株探米国株
英語
エドガーで原本を確認する
0001858028 false 0001858028 2022-09-21 2022-09-21 0001858028 NOVVU:UnitsEachConsistingOfOneOrdinaryShareParValue0.0001PerShareOneRedeemableWarrantEntitlingHolderToPurchaseOneHalfOfOrdinaryShareAndOneRightEntitlingHolderToReceiveOnetenthOfOrdinaryShareMember 2022-09-21 2022-09-21 0001858028 us-gaap:RightsMember 2022-09-21 2022-09-21 0001858028 NOVVU:OrdinarySharesMember 2022-09-21 2022-09-21 0001858028 NOVVU:WarrantsMember 2022-09-21 2022-09-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 21, 2022

 

Nova Vision Acquisition Corp.

(Exact Name of Registrant as Specified in its Charter)

 

British Virgin Islands   001-40713   N/A

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

3 Ocean Way #5-7

Singapore

  098368
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: +65 87183000

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

  

Title of each class   Trading Symbol(s)  

Name of each exchange on

which registered

Units, each consisting of one Ordinary Share, par value $0.0001 per share, one Redeemable Warrant entitling the holder to purchase one half of an Ordinary Share, and one Right entitling the holder to receive one-tenth of an Ordinary Share   NOVVU   NASDAQ Capital Market
Ordinary Shares   NOVV   NASDAQ Capital Market
Warrants   NOVVW   NASDAQ Capital Market
Rights   NOVVW   NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 4.01. Changes in Registrant’s Certifying Accountant.

 

Based on information provided by Nova Vision Acquisition Corp.’s (the “Company”) independent registered public accounting firm, Friedman LLP, effective September 1, 2022 Friedman LLP combined with Marcum LLP and continued to operate as an independent registered public accounting firm as a wholly-owned subsidiary of Marcum LLP. On September 21, 2022, the Board of Directors of the Company approved the dismissal of Friedman LLP and the engagement of Marcum LLP to serve as the independent registered public accounting firm of the Company. The services previously provided by Friedman LLP will now be provided by Marcum LLP.

 

Friedman LLP’s reports on the Company’s financial statements for the fiscal year ended December 31, 2021 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. Furthermore, during the Company’s most recent fiscal year and through September 23, 2022, there have been no disagreements with Friedman LLP on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to Friedman LLP’s satisfaction, would have caused Friedman LLP to make reference to the subject matter of the disagreement in connection with its reports on the Company’s financial statements for such periods.

 

For the fiscal year ended December 31, 2021 and through September 23, 2022, there were no “reportable events” as that term is described in Item 304(a)(1)(v) of Regulation S-K.

 

The Company provided Friedman LLP with a copy of the disclosure contained herein, prior to its filing with the Securities and Exchange Commission (the “Commission”), and requested that Friedman LLP furnish the Company a letter addressed to the Commission stating whether or not it agreed with the statements herein and, if not, stating the respects in which it does not agree. Friedman LLP’s letter to the Commission is attached hereto as Exhibit 16.1.

 

During the Company’s most recent fiscal year and through September 23, 2022, neither the Company nor anyone acting on the Company’s behalf consulted Marcum LLP with respect to any of the matters or reportable events set forth in Item 304(a)(2)(i) and (ii) of Regulation S-K.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
     
16.1   Letter, dated September 23, 2022, from Friedman LLP addressed to the Commission.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Nova Vision Acquisition Corp.
     
Dated: September 23, 2022   /s/ Eric Ping Hang Wong
    Eric Ping Hang Wong
    Chief Executive Officer and Chief Financial Officer

 

3

 

EX-16.1 2 ex16-1.htm

 

Exhibit 16.1

 

 

September 23, 2022

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

 

Re: Nova Vision Acquisition Corporation
  CIK No: 0001858028

 

Dear Sir or Madam:

 

We have read Form 8-K dated September 23, 2022 of Nova Vision Acquisition Corporation (“Registrant”) and are in agreement with the statements contained therein as it pertains to our firm.

 

We have no bias to agree or disagree with any other statements of the Registrant contained in Form 8-K.

 

/s/ Friedman LLP    
New York, New York